Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.67 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | RHOC | P08134 | 1/20 | 0.34 |
| ▸ | RHOA | P61586 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429499 | 0.90 | F10 (0.74) | F10ARHSD11B1TP53GRM5 | |
| SCHEMBL3425416 | 0.90 | F10 (0.67) | F10ARHSD11B1TP53GRM5 | |
| SCHEMBL3426646 | 0.89 | F10 (0.66) | F10ARHSD11B1TP53GRM5 | |
| SCHEMBL3423988 | 0.89 | F10 (0.68) | F10ARHSD11B1TP53RHOC | |
| SCHEMBL3422019 | 0.89 | F10 (0.70) | F10ARHSD11B1TP53GRM5 | |
| SCHEMBL3427728 | 0.86 | F10 (0.71) | F10ARHSD11B1TP53MAPT | |
| SCHEMBL3424110 | 0.86 | F10 (0.72) | F10ARHSD11B1AVPR2 | |
| SCHEMBL3428529 | 0.86 | F10 (0.72) | F10ARHSD11B1AVPR2 | |
| SCHEMBL3424674 | 0.86 | F10 (0.70) | F10ARHSD11B1RHOCRHOA | |
| SCHEMBL3426597 | 0.86 | F10 (0.72) | F10ARHSD11B1AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | F10 1901/4885AR 3491/4885HSD11B1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.